Our Reports: Russia Canned Meat Market Size, Share Report 2035 Electronic Warfare Market Size, Share, Growth, Forecast 2033 Germany Dimpleplasty Market Size, Share Forecasts To 2033
These items can slow weight loss and don't provide the satiety benefits of whole foods
In this GLP-1 round up: Oral GLP-1 delivers up to 12.4% weight loss in Phase III trial, offering injection-free alternative High-dose semaglutide achieves 25%+ weight loss in one-third of patients without added safety concerns FDA provides regulatory clarity for muscle-preserving drugs to break through the weight loss plateau WHO issues first recommendation for GLP-1s in obesity, framing it as chronic disease requiring long-term treatment Table of Contents New Drug Formulations and Clinical Trial Data Orforglipron: Phase III Data for Oral GLP-1 Eli Lillys orforglipron, an oral GLP-1 receptor agonist, reported Phase III results from the ATTAIN-1 trial in the New England Journal of Medicine
Major medical sources note very limited research on lipotropic injections for weight loss, and that any weight change is often more attributable to the overall program (nutrition, activity, calorie intake) than the injection alone
